Kymera Therapeutics
KYMR
$110.40
-7.50%
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation to develop novel medicines for diseases with known biology but previously undruggable targets. As a leader in the emerging degrader platform space, it leverages its proprietary technology to address high-value targets like STAT6 and IRAK4, distinguishing itself from traditional small-molecule approaches. The current investor narrative centers on the company's advancing pipeline, with recent clinical data readouts and partnership potential driving significant attention, while the stock's volatility reflects both the promise and risk inherent in early-stage biotech.…
KYMR
Kymera Therapeutics
$110.40
Investment Opinion: Should I buy KYMR Today?
Rating: Hold. Kymera is a speculative biotech with a promising platform but extreme valuation and binary risk. The analyst consensus is Buy, but the average target price is not explicitly provided; however, the implied forward PS of 22.9x suggests limited upside from current levels unless revenue materializes. The stock is not a clear buy for risk-averse investors.
Supporting Evidence: The trailing PS of 167.5x is unsustainable without significant revenue growth, while the forward PS of 22.9x requires achieving the average revenue estimate of $287.3 million. Revenue declined 61.3% YoY in Q4, and the company is unprofitable with a net margin of -30.4%. Free cash flow is deeply negative at -$234.34 million TTM. The stock's 164% one-year gain already prices in substantial optimism, leaving little margin for error.
Risks & Conditions: The biggest risks are clinical trial failure, valuation compression, and cash burn. This Hold would upgrade to Buy if the stock pulls back to $80 (near the 52-week low range) or if positive Phase 2 data is released, providing a clearer path to revenue. It would downgrade to Sell if revenue continues to decline or if a key trial fails. Overall, Kymera is overvalued relative to its current financials but fairly valued if pipeline milestones are achieved.
Sign up to view all
KYMR 12-Month Price Forecast
Kymera is a high-risk, high-reward biotech with a compelling platform but extreme valuation. The neutral stance reflects the balance between strong momentum and analyst support versus the binary risk of clinical outcomes and the stock's overbought technical condition. The base case of steady progress is most likely, but the wide target range underscores uncertainty. An upgrade to bullish would require positive clinical data or a significant pullback to a more reasonable valuation, while a downgrade to bearish would follow a trial failure or revenue miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kymera Therapeutics's 12-month outlook, with a consensus price target around $143.52 and implied upside of +30.0% versus the current price.
Average Target
$143.52
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$88 - $144
Analyst target range
Kymera is covered by 8 analysts, with a consensus leaning bullish. All recent ratings are Buy or Overweight, with no Sell or Hold ratings in the provided data. The average target price is not explicitly given, but based on the estimated EPS and revenue, the implied upside can be calculated. The average revenue estimate is $287.3 million, and the average EPS estimate is -$3.09. Using the current price of $119.35, the implied forward PS of ~22.9x suggests the market is pricing in that revenue level. The consensus recommendation is a Buy, indicating strong analyst confidence. The target range is not provided, but the high and low EPS estimates (-$0.52 to -$5.21) and revenue estimates ($103.3M to $438.2M) imply a wide range of outcomes. The high target likely assumes successful pipeline advancement and partnership milestones, while the low target reflects potential delays or failures. The wide spread indicates high uncertainty, typical for clinical-stage biotechs. Recent analyst actions show no downgrades; all actions are reiterations of Buy or Overweight, with one downgrade from Outperform to Peer Perform by Wolfe Research in January 2026. This suggests a generally positive but cautious sentiment. The lack of a specific price target range limits precision, but the bullish consensus and recent price surge imply that analysts see further upside, albeit with significant risk.
Bulls vs Bears: KYMR Investment Factors
Kymera Therapeutics presents a high-risk, high-reward profile typical of clinical-stage biotechs. The bull case rests on its innovative protein degradation platform, strong analyst support, and robust cash position, which could lead to significant upside if pipeline milestones are met. However, the bear case highlights extreme valuation (trailing PS 167.5x), declining revenue, widening losses, and technical overextension. Currently, the bull case has stronger evidence given the recent positive momentum and analyst consensus, but the single most important tension is whether upcoming clinical data (e.g., STAT6 or IRAK4) will validate the platform and justify the premium valuation. A positive readout could propel the stock higher, while a failure could lead to a sharp correction.
Bullish
- Innovative Platform with Blockbuster Potential: Kymera's targeted protein degradation platform addresses previously undruggable targets like STAT6 and IRAK4, offering a novel therapeutic approach. The market cap of $6.57 billion reflects significant upside potential if pipeline candidates succeed, with analyst revenue estimates averaging $287.3 million for the next fiscal year, implying a forward PS of ~22.9x.
- Strong Momentum and Analyst Confidence: The stock has surged 164% over the past year and 52.6% in the last month, far outpacing the S&P 500's 4.1% monthly gain. All 8 analysts rate it a Buy or Overweight, with no Sell ratings, indicating strong institutional conviction in the company's prospects.
- Robust Balance Sheet with Ample Cash Runway: Kymera holds $362.8 million in cash with a current ratio of 10.47 and negligible debt (debt-to-equity of 0.05). The $705.6 million raised in Q4 2025 provides a multi-year runway to fund clinical trials without near-term dilution risk.
- High Relative Strength vs. Market: The stock's relative strength over 1 year is 143.4%, meaning it has outperformed the S&P 500 by a wide margin. This sustained outperformance suggests strong underlying business momentum and investor enthusiasm for the degradation platform.
Bearish
- Extreme Valuation with Trailing PS of 167.5x: The trailing price-to-sales ratio of 167.5x is astronomically high compared to the biotech industry average of 5-10x. Even the forward PS of 22.9x requires massive revenue growth to justify, leaving little room for disappointment.
- Declining and Unpredictable Revenue Stream: Revenue fell 61.3% year-over-year in Q4 2025 to $2.86 million, with sequential declines from $22.1 million in Q1. As a pre-commercial biotech, revenue is lumpy and dependent on partnership milestones, making forecasting unreliable.
- Deep and Widening Losses with Cash Burn: Net loss widened to $87.03 million in Q4 2025 from $65.58 million in Q1, with negative free cash flow of $66.85 million in Q4 and -$234.34 million TTM. The company is not profitable and relies on external financing, though recent capital raise provides buffer.
- High Beta and Overbought Technical Signals: With a beta of 1.956, the stock is nearly twice as volatile as the market. The 52.6% one-month gain suggests overbought conditions, and the stock trades at 91.8% of its 52-week high, limiting near-term upside and increasing pullback risk.
KYMR Technical Analysis
Kymera is in a powerful sustained uptrend, with the stock up 164.0% over the past year and currently trading at $119.35, which is 91.8% of its 52-week range ($36.65–$130.05). This positioning near the top of the range signals strong momentum and bullish sentiment, though it also raises caution about potential overextension given the stock's beta of 1.956, indicating nearly double the volatility of the S&P 500. The price sits just 8.2% below the 52-week high, suggesting the uptrend remains intact but with limited near-term upside if resistance holds. Short-term momentum is exceptionally strong, with a 1-month price change of +52.6% and a 3-month change of +40.3%, both far outpacing the S&P 500's respective gains of 4.1% and 11.1%. This acceleration from the longer-term trend (1-year +164%) indicates a recent surge in buying pressure, likely driven by positive catalysts. The relative strength index (RSI) is not directly provided, but the magnitude of the 1-month move suggests overbought conditions, warranting caution for new entries. The 52-week low of $36.65 provides a major support level, while the 52-week high of $130.05 is the immediate resistance. A breakout above $130.05 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below the recent consolidation area near $100 could indicate a trend reversal. With a beta of 1.956, the stock is significantly more volatile than the market, meaning larger price swings and higher risk for position sizing.
Beta
1.96
1.96x market volatility
Max Drawdown
-27.7%
Largest decline past year
52-Week Range
$37-$130
Price range past year
Annual Return
+148.2%
Cumulative gain past year
| Period | KYMR Return | S&P 500 |
|---|---|---|
| 1m | +28.1% | +1.0% |
| 3m | +22.9% | +7.9% |
| 6m | +46.8% | +8.5% |
| 1y | +148.2% | +20.1% |
| ytd | +51.7% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KYMR Fundamental Analysis
Kymera's revenue trajectory is highly erratic and declining, with Q4 2025 revenue of $2.86 million representing a 61.3% year-over-year decline from $7.39 million in Q4 2024. The multi-quarter trend shows significant volatility: Q1 2025 revenue was $22.1 million, followed by $11.48 million in Q2, $2.76 million in Q3, and $2.86 million in Q4, indicating a sharp deceleration. As a pre-commercial biotech, revenue is primarily from collaborations and grants, not product sales, so the decline likely reflects the lumpy nature of partnership milestones. The investment case hinges on pipeline progress rather than current revenue, which is minimal and unpredictable. The company remains deeply unprofitable, with a net loss of $87.03 million in Q4 2025 and a net margin of -30.4%. Gross margin was 27.6% in Q4 2025, but this is misleading as cost of revenue includes R&D expenses; operating margin was -34.2%. Losses have been widening sequentially from -$65.58 million in Q1 2025 to -$87.03 million in Q4, reflecting increased R&D spending ($83.86 million in Q4). The company is not yet profitable and is burning cash, typical for clinical-stage biotechs. Kymera has a strong balance sheet with $362.8 million in cash as of Q4 2025, a current ratio of 10.47, and negligible debt (debt-to-equity of 0.05). However, free cash flow was negative $66.85 million in Q4 2025 and negative $234.34 million on a trailing twelve-month basis, indicating heavy cash burn. The company raised $705.6 million from financing in Q4 2025 (likely a stock offering), which bolstered its cash position. ROE is negative at -19.7%, reflecting persistent losses. The company is reliant on external financing to fund operations, but its current cash runway appears sufficient for the near term.
Quarterly Revenue
$2860000.0B
2025-12
Revenue YoY Growth
-61.32%
YoY Comparison
Gross Margin
2763.57%
Latest Quarter
Free Cash Flow
$-234340000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KYMR Overvalued?
Since Kymera has negative net income (EPS of -$0.98 in Q4 2025), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 167.5x, while the forward PS ratio is not directly provided but can be estimated from analyst revenue estimates (average $287.3 million for next fiscal year) implying a forward PS of ~22.9x. The gap between trailing and forward PS reflects the market's expectation of significant revenue growth, likely from pipeline milestones or partnerships. The stock trades at a massive premium to the biotech industry average PS ratio (typically around 5-10x for profitable companies, but higher for pre-revenue firms). With a PS of 167.5x trailing, it is far above the sector median, indicating the market is pricing in substantial future revenue. This premium may be justified by Kymera's innovative platform and potential blockbuster targets, but it also implies high expectations and risk. Historically, Kymera's PS ratio has ranged from around 31x (end of 2023) to over 2,295x (Q4 2025), reflecting the volatility of its revenue base. The current trailing PS of 167.5x is near the lower end of its recent range, suggesting that while still expensive, the valuation has compressed from extreme levels. The forward PS of ~22.9x is more reasonable but still requires significant revenue growth to materialize. The stock is not cheap by any traditional measure, but the valuation reflects the binary nature of biotech investing.
PE
-21.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -33x~-4x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Kymera's financial profile is characterized by deep losses and heavy cash burn. The net loss of $87.03 million in Q4 2025 and negative free cash flow of $66.85 million per quarter indicate a high burn rate, though the $362.8 million cash balance provides a runway of approximately 1-2 years. Revenue is minimal and declining (down 61.3% YoY), with no product sales, making the company entirely dependent on partnership milestones and future financing. The negative ROE of -19.7% and operating margin of -34.2% underscore persistent unprofitability. Any delay in pipeline progress or partnership payments could strain liquidity, despite the recent $705.6 million capital raise.
Market & Competitive Risks: The stock trades at a trailing PS of 167.5x, far above the biotech industry average, implying extreme growth expectations. If Kymera fails to deliver on pipeline milestones, the valuation could compress sharply, as seen in the 52-week low of $36.65 (69% below current price). The high beta of 1.956 means the stock is highly sensitive to market downturns and sector rotation. Competitive risks include other protein degradation companies (e.g., Arvinas, C4 Therapeutics) that may advance similar platforms. Regulatory risks are inherent in clinical-stage biotech, with any FDA hold or negative data readout potentially devastating.
Worst-Case Scenario: The most damaging scenario would be a clinical trial failure for a key asset (e.g., STAT6 or IRAK4), leading to a loss of investor confidence and a sharp sell-off. In such a case, the stock could fall to its 52-week low of $36.65, representing a 69.3% decline from the current price of $119.35. Additionally, if the company fails to secure new partnerships or financing, it may face dilution or bankruptcy. The historical max drawdown of -27.74% provides a less severe reference, but the binary nature of biotech means a complete loss of value is possible if the platform fails.
FAQ
The key risks are: 1) Clinical trial failure – a negative readout for STAT6 or IRAK4 could cause a 70%+ decline. 2) Valuation compression – the trailing PS of 167.5x leaves no room for error; any revenue miss could trigger a sharp re-rating. 3) Cash burn – negative free cash flow of $234 million TTM requires ongoing financing, though the recent $705.6 million raise provides near-term cushion. 4) High volatility – beta of 1.956 means the stock is nearly twice as volatile as the market, leading to large swings. The most severe risk is clinical failure, which could render the stock nearly worthless.
The 12-month forecast is highly uncertain, with three scenarios: Bull case (25% probability) – stock reaches $130-$160 on positive clinical data and partnerships. Base case (50% probability) – stock trades in a $100-$130 range as pipeline progresses without major catalysts. Bear case (25% probability) – stock falls to $37-$70 on a trial failure or revenue disappointment. The base case is most likely, but the wide range reflects the binary nature of biotech. Analyst consensus is Buy, but the lack of a specific average target price limits precision.
Kymera is overvalued based on current financials, with a trailing PS of 167.5x compared to the biotech industry average of 5-10x. However, the forward PS of 22.9x (based on analyst revenue estimates of $287.3 million) is more reasonable but still requires significant growth. The stock's valuation implies the market expects successful pipeline development and partnership revenue. Historically, the PS has ranged from 31x to over 2,295x, so the current level is near the lower end of its recent range, suggesting some compression. Overall, the stock is priced for perfection and is vulnerable to disappointment.
Kymera is a high-risk, high-reward biotech stock that may be suitable for aggressive investors with a long-term horizon. The stock has strong momentum (up 164% in one year) and analyst support (all Buy ratings), but its trailing PS of 167.5x is extremely high, implying significant growth expectations. The biggest downside risk is a clinical trial failure, which could send the stock to its 52-week low of $36.65 (69% below current price). For risk-tolerant investors who believe in the protein degradation platform, it could be a good buy on pullbacks, but conservative investors should avoid it due to the binary nature of the investment.
Kymera is more suitable for long-term investment (3-5 years) given its clinical-stage nature, as pipeline catalysts take time to materialize. The stock's high beta (1.956) and recent 52.6% one-month surge make it risky for short-term trading, as pullbacks can be sharp. Long-term investors can ride out volatility and benefit from platform validation, but must accept the risk of total loss. A minimum holding period of 3 years is recommended to allow for multiple clinical readouts. The stock pays no dividend, so it is not for income seekers.